Ian A. Critchley, PhD

Vice President, Clinical Microbiology
Spero Therapeutics

Disclosure: Spero Therapeutics (Employee, Shareholder)

Dr Critchley currently serves as Vice President and Head of Clinical Microbiology at Spero Therapeutics, a multi-asset, clinical stage biopharmaceutical company that is located in Cambridge, MA, and focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections. Dr Critchley’s team provides microbiology support for the company’s anti-infective pipeline. The current focus is directing pre-clinical and clinical microbiology studies in support of the most advanced asset, tebipenem-pivoxil hydrobromide (TBP-PI-HBr), an oral carbapenem being developed for the treatment of complicated urinary tract infections in an era of high prevalence of ESBL-producing gram-negative uropathogens and co-resistance to currently available oral antibiotics. Prior to joining Spero Therapeutics in April 2018, Dr Critchley served as Vice President of Clinical Microbiology at Allergan, plc where is teams contributed to the successful approval and launch of several antibiotics including Teflaro (ceftaroline-fosamil), Avycaz (ceftazidime-avibactam), Dalvance (dalbavancin) and Seysara (sarecycline). Dr. Critchley has more than 30 years’ experience in antibacterial drug development and obtained his PhD in Microbiology from the University of Glasgow, Scotland, UK.